Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2005, for eXegenics Inc. (Note: The input metadata referenced "OPKO HEALTH, INC.", but the filing text explicitly identifies the registrant as eXegenics Inc.). The company historically operated as a drug discovery firm but has been unsuccessful in advancing research programs. Management is currently focused on redeploying residual assets and identifying potential business opportunities. As of November 11, 2005, there were 16,877,818 shares of common stock outstanding.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2005 | Nine Months Ended Sep 30, 2005 | Balance Sheet (Sep 30, 2005) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Income (Loss) Attributable to Common | $871,000 | ($88,000) | N/A |
| Operating Loss | ($194,000) | ($1,008,000) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $8,954,000 |
| Total Assets | N/A | N/A | $9,131,000 |
| Total Liabilities | N/A | N/A | $22,000 |
| Net Cash from Operating Activities | N/A | ($217,000) | N/A |
Note: The filing text contains conflicting data regarding Net Cash from Operating Activities. The Statement of Cash Flows table lists ($217,000), while the Management Discussion and Analysis (MD&A) section states $220,000. The table value is derived directly from the financial statement.
Material Changes vs. Prior Period
- Profitability Shift: The company reported a net profit of $871,000 for the three months ended September 30, 2005, compared to a net loss of $368,000 in the same period in 2004. This reversal was driven entirely by a one-time gain on the sale of marketable securities, not operational revenue.
- Expense Reduction: General and administrative expenses decreased by 51% ($205,000) for the quarter and 42% ($720,000) for the nine-month period compared to 2004. Reductions were attributed to lower director and officer insurance, investor relations, and compensation costs due to having no employees.
- Investment Liquidation: Other income increased by approximately $1,039,000 for the quarter due to the sale of 337,100 shares of Javelin Pharmaceuticals, Inc. common stock. Consequently, marketable securities dropped from $1,124,000 at year-end 2004 to $54,000 at September 30, 2005.
- Liquidity: Cash and cash equivalents increased slightly from $8,734,000 (Dec 31, 2004) to $8,954,000 (Sep 30, 2005).
Outlook, Risks, and Contingencies
- Strategic Direction: Management is studying strategic direction and potential business opportunities as the company has ceased active drug discovery operations.
- Legal Contingency (Subsequent Event): On October 5, 2005, a jury ruled in favor of former employee Dr. Abdel Hakim Labidi, awarding him $600,000 for conversion and theft of biological materials. The company is reviewing the validity of an appeal. No provision has been made in the financial statements as the final amount is uncertain.
- Receivable Risk: A subscription receivable of $300,000 from a former CEO (Dr. Ronald Goode) is in default regarding interest payments. The balance is presented net of a reserve equal to the value of underlying collateral.
- Accounting Changes: The company expects to adopt SFAS 123R (Share-Based Payment) effective January 1, 2006, which will impact future financial statements.
Investor Verification Checklist
- Verify the status of the $600,000 legal judgment against the company and the likelihood of a successful appeal.
- Confirm the company's plan for redeploying residual assets, given the lack of operating revenue.
- Assess the collectability of the remaining subscription receivable from the former CEO.
- Monitor the impact of the upcoming adoption of SFAS 123R on future stock-based compensation expenses.
- Clarify the discrepancy between the Statement of Cash Flows ($217k outflow) and MD&A ($220k inflow) regarding operating cash flow.